Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Panbela Therapeutics, Inc. (CRSO) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Panbela Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1029125.
Total stock buying since 2015: $85,480.
Total stock sales since 2015: $1,091,983.
Total stock option exercises since 2015: $150,000.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 8,888 | $0 | 72,874 | $51,740 | 0 | $0 |
| 2022 | 165,000 | $0 | 0 | $0 | 0 | $0 |
| 2020 | 65,772 | $65,470 | 0 | $0 | 0 | $0 |
| 2019 | 68,570 | $0 | 343,411 | $1,030,233 | 0 | $0 |
| 2018 | 14,000 | $0 | 47,025 | $0 | 0 | $0 |
| 2017 | 0 | $0 | 0 | $0 | 80,000 | $150,000 |
| 2016 | 265,000 | $0 | 7,000 | $10,010 | 0 | $0 |
| 2015 | 200,118 | $20,010 | 517,266 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-11 | 0 | $0 | 72,874 | $51,740 | 0 | $0 |
| 2023-01 | 8,888 | $0 | 0 | $0 | 0 | $0 |
| 2022-10 | 165,000 | $0 | 0 | $0 | 0 | $0 |
| 2020-09 | 43,272 | $65,470 | 0 | $0 | 0 | $0 |
| 2020-06 | 12,500 | $0 | 0 | $0 | 0 | $0 |
| 2020-05 | 10,000 | $0 | 0 | $0 | 0 | $0 |
| 2019-09 | 37,142 | $0 | 0 | $0 | 0 | $0 |
| 2019-08 | 31,428 | $0 | 343,411 | $1,030,233 | 0 | $0 |
| 2018-08 | 0 | $0 | 47,025 | $0 | 0 | $0 |
| 2018-05 | 6,000 | $0 | 0 | $0 | 0 | $0 |
| 2018-02 | 8,000 | $0 | 0 | $0 | 0 | $0 |
| 2017-12 | 0 | $0 | 0 | $0 | 80,000 | $150,000 |
| 2016-11 | 0 | $0 | 7,000 | $10,010 | 0 | $0 |
| 2016-06 | 265,000 | $0 | 0 | $0 | 0 | $0 |
| 2015-09 | 0 | $0 | 517,266 | $0 | 0 | $0 |
| 2015-03 | 200,118 | $20,010 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-08 | Goldman Sachs & Co. Llc (10% Owner) | Sale | 72,874 | .71 | 51,740 |
| 2023-01-30 | Simpson Jennifer K. (President and CEO) | Buy | 4,444 | .00 | 0 |
| 2023-01-30 | Horvath Susan (V.P. of Finance & CFO) | Buy | 4,444 | .00 | 0 |
| 2022-10-04 | Cullen Michael T. (Director) | Buy | 165,000 | .00 | 0 |
| 2020-09-10 | Simpson Jennifer K. (President and CEO) | Buy | 1,000 | 2.74 | 2,737 |
| 2020-09-08 | Schaffer Paul W. (Director) | Buy | 225 | 2.55 | 573 |
| 2020-09-04 | Schaffer Paul W. (Director) | Buy | 24,775 | 2.51 | 62,160 |
| 2020-09-01 | Cullen Michael T. (Exec. Chairman, Pres. & CEO) | Buy | 10,000 | .00 | 0 |
| 2020-09-01 | Fratamico Arthur (Director) | Buy | 2,424 | .00 | 0 |
| 2020-09-01 | Simpson Jennifer K. (President and CEO) | Buy | 2,424 | .00 | 0 |
| 2020-09-01 | Horvath Susan (V.P. of Finance & CFO) | Buy | 2,424 | .00 | 0 |
| 2020-06-05 | Schaffer Paul W. (Director) | Buy | 10,000 | .00 | 0 |
| 2020-06-05 | Horvath Susan (V.P. of Finance & CFO) | Buy | 2,500 | .00 | 0 |
| 2020-05-22 | Cullen Michael T. (Exec. Chairman, Pres. & CEO) | Buy | 10,000 | .00 | 0 |
| 2019-09-20 | Gagnon Suzanne (Director) | Buy | 7,142 | .00 | 0 |
| 2019-09-20 | Schaffer Paul W. (Director) | Buy | 30,000 | .00 | 0 |
| 2019-08-30 | Cullen Michael T. (Exec. Chairman, Pres. & CEO) | Buy | 30,000 | .00 | 0 |
| 2019-08-30 | Horvath Susan (V.P. of Finance & CFO) | Buy | 1,428 | .00 | 0 |
| 2019-08-16 | Gilbertson Ryan Randall (10% Owner) | Sale | 343,411 | 3.00 | 1,030,233 |
| 2018-08-15 | Gilbertson Ryan Randall (10% Owner) | Sale | 47,025 | .00 | 0 |
| 2018-05-16 | Schaffer Paul W. (Director) | Buy | 5,000 | .00 | 0 |
| 2018-05-16 | Kaysen David B (President and CEO) | Buy | 1,000 | .00 | 0 |
| 2018-02-20 | Cullen Michael T. (Executive Chairman) | Buy | 5,000 | .00 | 0 |
| 2018-02-20 | Mathiesen Jeffrey S (Director) | Buy | 3,000 | .00 | 0 |
| 2017-12-13 | Gilbertson Ryan Randall (10% Owner) | Option Ex | 80,000 | 1.88 | 150,000 |
| 2016-11-14 | Schemel Donald Robert (Director) | Sale | 7,000 | 1.43 | 10,010 |
| 2016-06-24 | Cullen Michael T. (Executive Chairman) | Buy | 50,000 | .00 | 0 |
| 2016-06-24 | Gagnon Suzanne (Director) | Buy | 30,000 | .00 | 0 |
| 2016-06-24 | Schaffer Paul W. (Director) | Buy | 100,000 | .00 | 0 |
| 2016-06-24 | Kellen Scott (Chief Financial Officer) | Buy | 35,000 | .00 | 0 |
| 2016-06-24 | Kaysen David B (President and CEO) | Buy | 50,000 | .00 | 0 |
| 2015-09-01 | Sargent Robert John | Sale | 216,705 | .00 | 0 |
| 2015-09-01 | Fuhrman David Michael | Sale | 300,561 | .00 | 0 |
| 2015-03-01 | Sargent Robert John | Buy | 100,059 | .10 | 10,005 |
| 2015-03-01 | Fuhrman David Michael (President and CEO) | Buy | 100,059 | .10 | 10,005 |
Insider trading activities including stock purchases, stock sales, and option exercises of CRSO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Panbela Therapeutics, Inc. (symbol CRSO, CIK number 1029125) see the Securities and Exchange Commission (SEC) website.